Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab to Treat Sporadic Inclusion Body Myositis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* Only patients who are currently enrolled in protocol 02-N-0121 Study of Immune Dysregulation in Patients with Sporadic Inclusion Body Myositis (s-IBM) will be considered for enrollment in protocol 04-N-0133.~INCLUSION CRITERIA:~Patients with confirmed diagnosis of s-IBM willing to undergo therapy with Alemtuzumab.~Willingness and legal ability to give and sign informed study consent.~Willingness to travel to the Clinical Center for planned studies and treatment as required by protocol.~Men and women of reproductive potential must agree to use an acceptable method of birth control during and for six months after completion of treatment.~Availability of tissue for testing. This will include muscle and peripheral blood lymphocytes isolated through routine lymphocytapheresis or phlebotomy.~EXCLUSION CRITERIA:~Immunosuppressive drug therapy at the time of or 6 months prior to enrollment. Specifically, candidates may not be taking Prednisone, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, anti-lymphocyte agents, cyclophosphamide methotrexate, or other agents whose concomitant use may enhance the toxicity of Alemtuzumab.~Any medical or personal difficulties that precludes serial follow-up visits.~Any active malignancy.~Significant coagulopathy or requirement for anticoagulation therapy that would contraindicate protocol.~Platelet count less than 100,000/mm(3).~Hemoglobin less than 9.0 mg/dl.~Any known immunodeficiency syndrome included HIV infection.~Any history of cardiac insufficiency, major vascular disease, or unstable coronary artery disease.~Any history of systemic or pulmonary edema.~Any history of previous treatment with monoclonal antibodies or sensitivity to the study drug (Alemtuzumab), pre-medication regimen, or prophylactic agents.~History of chronic hypotension (SBP less than 100 mmHg).~Any medical condition that would likely increase the risk of side effects of the study drug or confound the interpretation of the data including active infections.~Pregnancy and active nursing (breast feeding).~History of uncontrolled thyroid disease or a history of autoimmune thyroiditis.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).